Compare Novo Nordisk A/S (NVO) vs iShares Semiconductor ETF (SOXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs iShares Semiconductor ETF — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while iShares Semiconductor ETF trades at $551.35. The key difference: Novo Nordisk A/S pays a 3.63% dividend while iShares Semiconductor ETF pays none, and iShares Semiconductor ETF is trading nearer its 52-week high, Novo Nordisk A/S nearer its low. Which is the better fit depends on your goals.
| NVO | SOXX | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | Sector/Thematic |
52-Week High | $71.70 | $655.01 |
52-Week Low | $35.29 | $236.93 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
SOXX trades at $524.14, up 0.45% with a bearish technical signal from moving averages. The semiconductor ETF faces volatility amid AI sector rotation, with RSI levels below 30 suggesting potential oversold conditions. Recent news highlights semiconductor leadership in market rebounds but also bear market concerns, with the ETF down 20% from June highs. Support levels cluster around $518-$512, while resistance begins at $529.
Outlook remains cautious due to sector concentration risks and cyclical pressures, though oversold technicals may offer near-term bounce potential. Key risks include AI trade volatility, China export controls, and hyperscaler capex pressures. Analyst views are mixed, with some highlighting long-term growth prospects despite recent underperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About iShares Semiconductor ETF
SOXX provides investors with exposure to U.S. companies that design, manufacture, and distribute semiconductors. It tracks the ICE Semiconductor Index, offering a targeted investment in the technology sector's foundational components, including firms that produce chips, related equipment, and services. SOXX is a key vehicle for investors seeking to capitalize on trends in artificial intelligence, 5G, and other technologies that rely heavily on advanced semiconductor technology.
Read more on SOXX →
